Background: A clinically relevant bleeding diathesis is a frequent diagnostic
Introduction
A clinically relevant bleeding diathesis is a frequent diagnostic challenge and identification of its etiology may be difficult (1) . To assess the cause of bleeding a comprehensive clinical evaluation and a sequential laboratory work-up are necessary. Accurate acquisition of medical history is the first essential step. For this purpose, bleeding questionnaires have been developed and validated in clinical practice (2, 3) . In addition, standard laboratory tests are helpful to detect disorders of primary hemostasis or coagulation factor defects (4, 5) . However, identification of clinically relevant disorders of primary hemostasis may be difficult and work-up of a patient with a significant bleeding diathesis fails sometimes to detect an explanatory cause (1) . The difficulty to determine the etiology is more pronounced if the bleeding is caused by a platelet dysfunction. A variety of different aspects of the platelet function can be impaired on a genetic basis (6) and multiple factors have an impact on the clinical phenotype -e.g., dietary and metabolic variables, smoking, inflammation, drugs, and other components of the hemostatic system (7) . Because knowledge of bleeding's etiology is a prerequisite for optimal patient management, efforts to improve laboratory diagnostic procedures have been made. Presently various platelet function assays are available and the combination of multiple tests provides information about platelet function as a whole. Flow cytometric analysis is a very helpful tool in the diagnostic work-up of hematologic malignancies and several studies have shown its utility in diagnosing platelet defects as well (8) (9) (10) .
At our institution a standardized procedure with step by step diagnostic is applied to out-patients referred for clarification of a bleeding diathesis (Figure 1 ). Acquisition of a detailed medical history and clinical examination are followed by analysis of plasmatic coagulation factors, including von Willebrand factor and whole blood 7 
Blood samples
Blood was collected by standard venepuncture into EDTA for blood cell count (Monovette, Sarstedt, Nümbrecht, Germany), 0.106 M tri-sodium citrate (9:1 vol/vol) in plastic syringes for standard coagulation and platelet flow-cytometric assays (Monovette, Sarstedt, Nümbrecht, Germany), and buffered citrate for platelet aggregation studies (0.13 M tri-sodium citrate, pH 5.5).
Analysis of coagulation parameters
Details on coagulation assays performed in our laboratory have already been published (11) . Clotting activities of factors VIII:C, IX:C, and XI:C were measured by a one stage clotting method, using factor deficient plasma (Siemens Healthcare automated test system on a VIDAS analyzer (bioMérieux Suisse SA, Genève, Switzerland). Activity of α 2 -antiplasmin was measured by a chromogenic assay which was performed on a Behring Coagulation System (BCS) automated analyzer (Siemens Healthcare Diagnostics) after adding a defined amount of plasmin (Siemens Healthcare Diagnostics) to the patient's sample. As a standard, plasma 8 control samples of healthy donors with a defined α 2 -antiplasmin concentration were run in parallel.
Platelet function analyzer (PFA)
The PFA is a high shear-inducing test of platelet adhesion and aggregation (12) . This test system is sensitive to a large number of variables like platelet count and function, von Willebrand factor defects, and hematocrit. Therefore testing was always performed with knowledge of full blood count and after a 10 days wash-out period of any compound known to affect platelet function. The test system consists of a microprocessor-controlled instrument (PFA-100 ® and INNOVANCE ® PFA-100™
System, Siemens Healthcare Diagnostics, Germany) and a disposable test cartridge.
We used two types of cartridges (Dade® PFA collagen/epinephrine, and Dade® PFA collagen/ADP, Siemens Healthcare Diagnostics, Germany) for all patients. In response to stimulation by collagen, together with either epinephrine or ADP, as well as by high shear rates, VWF and platelets become activated and adhere on the membrane surface in the test cartridge. Ultimately a platelet plug gets formed, occludes the aperture and the blood flow is stopped. The closure times (CT) for epinephrine and for ADP, which are defined as the time that is required to obtain occlusion of the aperture, were measured in two buffered citrated whole blood samples of each patient.
Light transmission platelet aggregation tests (LTA) in platelet rich plasma (PRP)
LTA testing was performed as already described in the literature (13, 14) . Specifically, venous blood samples were collected into buffered 0.13 M tri-sodium citrate in a ratio of 1:9 (1 part anticoagulant to 9 parts blood), transported to the laboratory at room temperature (RT) and processed immediately. PRP was prepared by centrifugation at 9 RT for 15 minutes at 150g. The PRP was carefully removed, placed into another plastic tube and stored at RT. In the PRP, the platelet count was adjusted to 250 x10 9 /l with platelet poor plasma (PPP), prepared by further centrifugation of the remaining plasma at 1500g for 15 minutes at RT. In case of platelet counts between 100 and 250 x10 9 /l, the count was not further corrected but documented on the protocol. In individuals with low platelet counts below 100 x10 9 /l an additional centrifugation with 150g at RT for 5 minutes was performed (15) .
The aggregometer (APACT 4004®, LABiTec GmbH, Ahrensburg, Germany) was then calibrated by using a cuvette containing PRP which equates to 0% light transmission and by using a second cuvette containing PPP which equates to 100% light transmission. concentrations were 1.5 mg/ml and 0.5 mg/ml. Two-hundred µL of PRP pre-warmed at 37°C for 1 min was added to the aggregometer cuvette and run for an additional minute in order to exclude spontaneous aggregation. Thereafter, 20 µL of the agonist was added and the response recorded. If the response to one agonist was out of normal range, the test was repeated once more either to confirm the result or to rule out technical failures. Normally, LTA started 1 hour after having drawn the venous blood samples from the patient and was completed within 2.5 hours. For interpretation of the platelet aggregation traces we used standardized in-house algorithms taking into account our validation (15) and published guidelines (13, 14) . nM (16) . Based on 40 control subjects we defined the ability to generate <20% COAT platelets as "decreased" (Table 1) .
Statistical analysis
Results are expressed as median ± interquartile range (IQR), minimum-maximum (min-max) or mean ± standard deviation (SD). Statistical analyses were performed with SigmaStat (version 3.5; Systat Software Inc., San Jose, CA, USA) using non parametric tests. P <0.05 was considered statistically significant.
Results
We developed an extensive flow-cytometric analysis (FCA) of platelet phenotypic and functional characteristics (Figures 2 and 3) . Table 1 whereas in 38 patients (57%) was abnormal (Table 1) . Thirty-three patients had a borderline result in platelet aggregation after stimulation with ADP. Less frequently borderline aggregation patterns were seen after stimulation with collagen (n=27), arachidonic acid (n=11), and ristocetin (n=8). In 28 out of 38 individuals (74%) with borderline LTA-PRP, more than one agonist showed an abnormal aggregation curve.
However, these borderline results did not allow to clearly establish the presence of a platelet function defect.
Results of FCA are summarized in Table 2 and Figure 4 . FCA did not reveal any defect in the surface density of the receptors for fibrinogen (GPIIb-IIIa) and VWF (GPIb-IX-V), and was completely normal in 18 out of the 67 (27%) patients (Table 2 and Fig. 4) . FCA of platelet function was borderline in 2 (3%) and showed abnormal results in 47 (70%) patients.
Overall, the dense-granule content (detected by mepacrine stain) was <70% compared to control platelets in 9 out of 67 patients (13%): three of 29 (10%) patients with normal LTA-PRP and 6 of 38 (16%) patients with borderline LTA-PRP.
Thrombin-induced secretion of dense-granules was reduced <90% in 3 patients (10%) with normal LTA-PRP and in 2 (5%) with borderline LTA-PRP.
Secretion of α-granules (detected by P-selectin surface expression) was evaluated after platelet activation by graded concentrations of ADP, convulxin and thrombin.
Among the patients with normal LTA-PRP, 5 out of 29 patients (17%) had a decreased α-granule secretion <40% after exposure to ADP. In contrast, only one of these patients showed an impaired α-granule secretion after activation with thrombin Procoagulant COAT platelets were generated by simultaneous platelet activation with convulxin and thrombin as already described in materials and methods. Overall, 16 out of 67 (24%) patients showed a decreased procoagulant platelet activity (Table 2 and Fig. 4 ). For comparison, the prevalence of COAT platelet levels <20% among normal controls employed for generating in-house cut-offs was 2/40 (p=0.024, Chisquare; see Table 1 ) and 9/100 in platelet donors serving as daily controls for diagnostic FCA (p=0.015, Chi-square; median 27%; range 15% -57%; 2.5 th percentile 17% and 5 th percentile 18%).
For better visualization of the clustering of multiple defects in individual patients and in order to illustrate the relative frequency of potential platelet defects, we tabulated
Discussion
Investigation of a bleeding diathesis includes several diagnostic steps and laboratory assays to identify its etiology (4, 5) . However, there is still a substantial percentage of patients having a positive bleeding diathesis in whom laboratory work-up is unable to detect a causative disorder (1).
In this study we evaluated the diagnostic utility of an extensive phenotypic and functional characterization of platelets by flow cytometry in patients with a clinically significant bleeding diathesis but non-diagnostic standard laboratory investigations.
We show that flow cytometric analysis (FCA) is able to identify several potentially explanatory platelet function defects ( Table 2 and Fig. 4 ). However, we would also point out that among 18/67 patients (27%) FCA of platelet function was normal, indicating that either platelet defects not detectable by this technique or vessel wall defects could be responsible for the bleeding diathesis.
First, we have identified dense-granule defects in 13 out of 67 patients (19%): in 8 patients as an isolated anomaly and in 5 combined with other platelet function defects (Fig. 4) . This observation confirms that symptomatic patients with normal platelet aggregation frequently have a storage pool disease (20, 21) and is in line with the recommendation that platelet nucleotides content and release should specifically be investigated if aggregation studies are unrevealing (4,5).
Second, we have observed some peculiar functional anomalies, which may point to the underlying specific defect. For instance, a single patient with an isolated impairment of GPIIb/IIIa activation with all agonists (#59 Fig. 4A ), suggesting a dysfunctional fibrinogen receptor. A patient with a decreased ADP-induced platelet activation (#22 Fig. 4B ) and another with a reduced convulxin-induced activation (#64 Fig. 4B ), suggesting an involvement of the respective receptors. Other anomalies point to hypothetical defects in the pathways of specific agonist-induced activation end-points: for instance, secretion of α-granules by ADP (#15, #28, and #55 Figure   4A and #46 Figure 4B ) or convulxin (#05 Fig. 4A and #44 Fig. 4B ), and activation of the fibrinogen-receptor induced by ADP (#32 Fig. 4A and #45, #48, #50 Fig. 4B ), convulxin (#20 Fig. 4A and #27 and #19 Fig. 4B ) or thrombin (#37 Fig 4B) . It is reasonable to speculate, that these distinct clusters point to the underlying defect and that elucidation of the involved pathway may lead to the identification of the pathogenic mechanism.
Third, we report that platelet α-granule secretion in response to the weak agonist ADP is more variable than that to thrombin or convulxin (Table 1) and that some patients show borderline results close to the cut-off values (Table 2 ). This is compatible with the hypothesis of minor platelet function defects, which are not detected by conventional platelet function studies but could lead to clinical relevant bleeding, especially if concomitant causes, such as surgical challenges, drugs or minor defects in other components of the hemostatic system are present (7).
The fourth and to us most fascinating observation is that a substantial proportion of the investigated patient (16/67, 24%) show a decreased ability to produce COAT platelets ( Table 2) . COAT platelets are a subpopulation of platelets, generated by combined activation with collagen and thrombin, which are very effective in sustaining thrombin generation (16) . COAT platelets retain high levels of α-granule proteins on their surface, including factor V, fibrinogen and von Willebrand factor (VWF) by a serotonin-and transglutaminase-dependent mechanism (22) . Among healthy individuals, Dale and his colleagues described, similarly to our results (Table   1) , an average of 33% COAT platelets and noted that the amount of an individual's COAT platelets seems to be stable over time (19) .
The potential clinical relevance of COAT platelets in hemostasis is revealed by the work of Dale and Prodan. Their investigations have shown a link between COAT platelet level and the appearance of spontaneous intracerebral hemorrhages (23) and bleed volume (24) . A low level of COAT platelets is also correlated with lacunar stroke morphology (18) and early hemorrhagic transformation in non-lacunar strokes (25) . On the other hand, a high amount of COAT platelets seems to correlate with transient ischemic attack and ischemic stroke (26, 27) . Recently, the same group found a higher level of COAT platelets in patients with subarachnoid hemorrhage and described an increased 30-day mortality in association with the amount of COAT platelets in these patient population (28) . Finally, COAT platelets appear to have an impact on the bleeding phenotype in severe haemophilia (29) . However, to draw robust conclusions about how individual differences in the level of COAT platelets contributes to a hemorrhagic or thrombotic phenotype, more clinical data are still required.
In the present work we identified 16 out of 67 (24%) patients with a clinically significant bleeding diathesis but unrevealing laboratory work-up, who generated <20% COAT platelets. Of note, in the majority of them this was the only anomaly identified (n=10) and in the remainders it was usually associated with just a single additional platelet activation defect (Fig. 4) . Since platelets of all 16 patients showed normal surface expression of negatively charged phospholipids upon activation with ionophore A23187 this is not a primary defect in platelet procoagulant activity, such as in Scott Syndrome (30, 31) . We hypothesize that the impaired ability to generate procoagulant COAT platelets is likely to be secondary to an insufficient intracellular calcium rise upon combined activation with convulxin and thrombin. We are currently searching for causative defects (32).
This work, showing a significantly higher prevalence of an impaired ability to generate COAT platelets in patients with a bleeding diathesis (16/67) than in normal controls (2/38 and 9/100; p=0.024 and 0.015, respectively) underscores the role of platelet procoagulant activity for the formation of a stable hemostatic plug. Of note, platelets ability to differentially regulate thrombin generation is an increasingly recognized aspect of hemostasis and thrombosis (33) , beside their ability to adhere and aggregate.
In perspective, COAT platelets could represent an interesting therapeutic target. If elevated COAT platelets will be shown to be independently associated with arterial thrombotic disease, drugs that specifically inhibit the mechanisms of platelet procoagulant transformation would result in potential new antithrombotic therapies.
Conversely, up-regulating COAT platelet generation might be expected to represent a therapeutic option for patients suffering from bleeding diathesis (Colucci et al.
Manuscript submitted). Finally, in vitro studies have shown that recombinant FVIIa preferentially binds to procoagulant platelets (34, 35) , and similar preferential binding to COAT platelets has been described for vatreptacog alfa, a novel recombinant FVIIa variant (36) . Taking these data into account, the individual level of COAT platelets might be an important component for explaining the difference in hemostatic response to these drugs. 20 In summary, we show that phenotypic and functional platelet analysis by flow cytometry among patients with a significant bleeding diathesis and non-diagnostic standard laboratory work-up is able to identify potentially explanatory defect. We confirm that storage pool defects are frequent and should be searched in this population (in this report 19%). In addition, we show for the first time that a relevant proportion of these patients present with an isolated impairment of their ability to generate COAT platelets (in this report 24%). This is a conceptually novel ( 
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